Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Diagnostic PET Imaging of Mammary Microcalcifications Using 64Cu-DOTA-Alendronate in a Rat Model of Breast Cancer.

Ahrens BJ, Li L, Ciminera AK, Chea J, Poku E, Bading JR, Weist MR, Miller MM, Colcher DM, Shively JE.

J Nucl Med. 2017 Sep;58(9):1373-1379. doi: 10.2967/jnumed.117.190850. Epub 2017 Apr 27.

2.

High-Throughput Analysis of Plasma Hybrid Markers for Early Detection of Cancers.

Rho JH, Lampe PD.

Proteomes. 2014 Jan 13;2(1):1-17. doi: 10.3390/proteomes2010001. Review.

3.

Analysis of binary responses with outcome-specific misclassification probability in genome-wide association studies.

Rekaya R, Smith S, Hay EH, Farhat N, Aggrey SE.

Appl Clin Genet. 2016 Nov 30;9:169-177. eCollection 2016.

4.

Short-term Follow-up US Leads to Higher False-positive Results Without Detection of Structural Recurrences in PTMC.

Yoon JH, Lee HS, Kim EK, Youk JH, Kim HG, Moon HJ, Kwak JY.

Medicine (Baltimore). 2016 Jan;95(1):e2435. doi: 10.1097/MD.0000000000002435.

5.

Risk perception and psychological morbidity in men at elevated risk for prostate cancer.

Matthew AG, Davidson T, Ochs S, Currie KL, Petrella A, Finelli A.

Curr Oncol. 2015 Dec;22(6):e462-9. doi: 10.3747/co.22.2679.

6.

Nonmedical information seeking amid conflicting health information: negative and positive effects on prostate cancer screening.

Gibson L, Tan AS, Freres D, Lewis N, Martinez L, Hornik RC.

Health Commun. 2016;31(4):417-24. doi: 10.1080/10410236.2014.963786. Epub 2015 Sep 11.

7.

Sources of variation in follow-up expenditure after radical cystectomy.

Vemana G, Vetter J, Chen L, Sandhu G, Strope SA.

Urol Oncol. 2015 Jun;33(6):267.e31-7. doi: 10.1016/j.urolonc.2015.03.009. Epub 2015 Apr 20.

8.

Time to benefit for colorectal cancer screening: survival meta-analysis of flexible sigmoidoscopy trials.

Tang V, Boscardin WJ, Stijacic-Cenzer I, Lee SJ.

BMJ. 2015 Apr 16;350:h1662. doi: 10.1136/bmj.h1662. Erratum in: BMJ. 2015;350:h2228.

9.

Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.

Doseeva V, Colpitts T, Gao G, Woodcock J, Knezevic V.

J Transl Med. 2015 Feb 12;13:55. doi: 10.1186/s12967-015-0419-y.

10.

Recommendations on screening for prostate cancer with the prostate-specific antigen test.

Bell N, Connor Gorber S, Shane A, Joffres M, Singh H, Dickinson J, Shaw E, Dunfield L, Tonelli M; Canadian Task Force on Preventive Health Care.

CMAJ. 2014 Nov 4;186(16):1225-34. doi: 10.1503/cmaj.140703. Epub 2014 Oct 27. No abstract available.

11.

Screening tests: a review with examples.

Maxim LD, Niebo R, Utell MJ.

Inhal Toxicol. 2014 Nov;26(13):811-28. doi: 10.3109/08958378.2014.955932. Epub 2014 Sep 29. Review.

12.

Prostate specific antigen: the past, present and future.

Gill H, Wu J.

Curr Urol. 2013 Feb;6(4):175-8. doi: 10.1159/000343535. Epub 2013 Feb 8. Review.

13.

Chemical nose sensors: an alternative strategy for cancer diagnosis.

Le ND, Rana S, Rotello VM.

Expert Rev Mol Diagn. 2013 Mar;13(2):111-3. doi: 10.1586/erm.12.143. No abstract available.

14.

Identification of potential glycan cancer markers with sialic acid attached to sialic acid and up-regulated fucosylated galactose structures in epidermal growth factor receptor secreted from A431 cell line.

Wu SL, Taylor AD, Lu Q, Hanash SM, Im H, Snyder M, Hancock WS.

Mol Cell Proteomics. 2013 May;12(5):1239-49. doi: 10.1074/mcp.M112.024554. Epub 2013 Jan 31.

15.

Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Barry SA, Tammemagi MC, Penek S, Kassan EC, Dorfman CS, Riley TL, Commin J, Taylor KL.

J Natl Cancer Inst. 2012 Nov 7;104(21):1647-59. doi: 10.1093/jnci/djs398. Epub 2012 Oct 26.

16.

Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy.

Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O'Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD; PLCO Project Team.

N Engl J Med. 2012 Jun 21;366(25):2345-57. doi: 10.1056/NEJMoa1114635. Epub 2012 May 21.

17.

Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination.

Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Doria-Rose VP, Laiyemo AO, Church T, Yokochi LA, Yurgalevitch S, Rathmell J, Andriole GL, Buys S, Crawford ED, Fouad M, Isaacs C, Lamerato L, Reding D, Prorok PC, Berg CD; PLCO Project Team.

J Natl Cancer Inst. 2012 Feb 22;104(4):280-9. doi: 10.1093/jnci/djr549. Epub 2012 Jan 31.

18.

Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer.

Xu JL, Commins J, Partridge E, Riley TL, Prorok PC, Johnson CC, Buys SS.

Gynecol Oncol. 2012 Apr;125(1):70-4. doi: 10.1016/j.ygyno.2011.12.440. Epub 2011 Dec 22.

19.

Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks).

Allan GM, Chetner MP, Donnelly BJ, Hagen NA, Ross D, Ruether JD, Venner P.

Can Urol Assoc J. 2011 Dec;5(6):416-21. doi: 10.5489/cuaj.11063.

20.

Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST).

Kramer BS, Berg CD, Aberle DR, Prorok PC.

J Med Screen. 2011;18(3):109-11. doi: 10.1258/jms.2011.011055. No abstract available.

Supplemental Content

Support Center